Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?
G Colafigli, E Scalzulli, A Di Prima, S Pepe… - Critical Reviews in …, 2021 - Elsevier
Tyrosine kinase inhibitors (TKIs) have drastically changed the outcome of chronic myeloid
leukemia (CML) patients. A sustained and deep molecular response achieved over time …
leukemia (CML) patients. A sustained and deep molecular response achieved over time …
Monitoring chronic myeloid leukemia: how molecular tools may drive therapeutic approaches
B Izzo, EM Gottardi, S Errichiello, F Daraio… - Frontiers in …, 2019 - frontiersin.org
More than 15 years ago, imatinib entered into the clinical practice as a “magic bullet”; from
that point on, the prognosis of patients affected by chronic myeloid leukemia (CML) became …
that point on, the prognosis of patients affected by chronic myeloid leukemia (CML) became …
Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient
D Russo, M Malagola, N Polverelli… - Therapeutic …, 2023 - journals.sagepub.com
The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
X Dou, Y Qin, X Huang, Q Jiang - The Oncologist, 2019 - academic.oup.com
Background The aim of this study was to explore outcomes of planned pregnancy in female
patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitors (TKIs). Materials …
patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitors (TKIs). Materials …
The potential of exosomes derived from chronic myelogenous leukaemia cells as a biomarker
Background/Aim: Exosomes, derived from chronic myelogenous leukaemia (CML) cells, can
be used as biomarkers and new targets for the detection of the BCR-ABL transcript. This …
be used as biomarkers and new targets for the detection of the BCR-ABL transcript. This …
Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma
S Bal, A Weaver, RF Cornell… - British journal of …, 2019 - Wiley Online Library
Treatment response assessment in multiple myeloma (MM) relies on the detection of
paraprotein in serum and/or urine, bone marrow morphology and immunohistochemistry …
paraprotein in serum and/or urine, bone marrow morphology and immunohistochemistry …
Immunomodulatory effects of IFNα on T and NK cells in chronic myeloid leukemia patients in deep molecular response preparing for treatment discontinuation
MC Puzzolo, M Breccia, P Mariglia, G Colafigli… - Journal of Clinical …, 2022 - mdpi.com
A deep and stable molecular response (DMR) is a prerequisite for a successful treatment-
free remission (TFR) in chronic myeloid leukemia (CML). In order to better identify and …
free remission (TFR) in chronic myeloid leukemia (CML). In order to better identify and …
The rising prevalence of chronic myeloid leukemia in France
M Delord, S Foulon, JM Cayuela, P Rousselot… - Leukemia research, 2018 - Elsevier
Outcomes in chronic myeloid leukemia (CML) have been dramatically improved since the
emergence of imatinib and the subsequent generation of tyrosine kinase inhibitors (TKI) in …
emergence of imatinib and the subsequent generation of tyrosine kinase inhibitors (TKI) in …
Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication
MY Lee, CJ Park, YU Cho, E You, S Jang… - Cancer Immunology …, 2020 - Springer
Malignant cells can increase in number using immune escape mechanisms such as immune
checkpoints. In this study, we evaluated the expression of an immune checkpoint …
checkpoints. In this study, we evaluated the expression of an immune checkpoint …
Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
R Sogawa, S Kimura, R Yakabe, Y Mizokami… - International journal of …, 2018 - Springer
Background ABL tyrosine kinase inhibitors (TKIs) significantly changed the prognosis of
patients with chronic myeloid leukemia (CML), and clinical trials demonstrated that TKIs can …
patients with chronic myeloid leukemia (CML), and clinical trials demonstrated that TKIs can …